The FDA milestones deck: one slide, three answers, no biotech jargon

Generalist VCs want three things from an FDA milestones deck slide: device class, regulatory pathway, and a named commercial precedent. Most biotech decks bury all three under jargon. This guide gives you the one-slide template that answers all three in 15 seconds, with two good examples and two teardowns from decks that got passed on.

Most biotech founders lose the room in the first 90 seconds of the regulatory slide. The cause is always the same: the slide lists acronyms before answering the three questions every generalist VC has already decided to ask. You can fix this in one slide. Your FDA milestones deck does not need a timeline, a gantt, or a reg-affairs org chart. It needs a class, a pathway, and a comp.

What generalist VCs actually ask about FDA

Three questions, in this order: what class, what pathway, what is the closest comp. Partners without a biotech background use these as proxies for time-to-revenue and binary risk. Answer them in the first line of the slide and you buy yourself the rest of the meeting.

• Class: FDA Class I, II, or III. Class drives which controls apply and how much clinical data you need.
• Pathway: 510(k), De Novo, or PMA. Pathway drives timeline and cost.
• Comp: a named public or acquired company that cleared the same pathway for an analogous device.

If your slide cannot be summarized in one sentence of the form "we are a Class II device pursuing 510(k) clearance, the same pathway iRhythm used for Zio XT," rewrite it. The iRhythm Zio XT 510(k) is public; the predicate number (K190593) is free to cite.

The one-slide FDA pathway slide template

An FDA pathway slide is a single slide that states device class, submission pathway, expected clearance timeline, and one named commercial precedent. It is not a regulatory strategy document. Its job is to let a generalist VC form a time-to-revenue estimate in 15 seconds. Everything else belongs in the data room.

Structure it in four lines:

1. Classification. One line: "Class II, 21 CFR 870.2900, cardiac monitor."
2. Pathway. One line: "510(k) premarket notification. Predicate: Zio XT, K190593."
3. Timeline to clearance. One line with a bounded date range, not a gantt. Include the pre-submission FDA (Q-Sub) meeting as a dated milestone.
4. Commercial precedent. One line: a public or acquired company with the same class and pathway.

Anything beyond this belongs on an appendix slide titled "regulatory deep dive."

510k vs PMA vs De Novo, explained for the deck

Use the pathway name that matches your device. Do not pick the one that sounds most impressive on a slide.

A De Novo classification request is the marketing pathway for novel devices where general or special controls provide reasonable assurance of safety and effectiveness (FDA). Use the word "De Novo" only if your device genuinely has no predicate. Calling a clean 510(k) a De Novo to sound differentiated is how founders get caught on diligence.

Therapeutics founders: substitute IND and NDA for 510(k) and PMA. The IND pitch deck version of this slide follows the identical four-line structure, with pre-IND meeting and Phase 1 readout replacing pre-submission and clearance.

Good examples vs rejected decks, two of each

Four real-pattern teardowns. The pattern is the same every time: specificity wins, vagueness loses.

✅ Good: "Class II, 510(k), predicate Zio XT (K190593). Filing Q2 2026, clearance expected Q4 2026 to Q1 2027." Names the pathway, the predicate, and a bounded timeline.

❌ Bad: "Pursuing FDA clearance via the appropriate regulatory pathway, leveraging extensive clinical validation." No class, no pathway, no date. Generalist VCs read this as "we do not know yet."

✅ Good: "Class III, PMA, modeled on Edwards Lifesciences transcatheter valve clearance cycle. Pivotal trial readout Q3 2027, submission Q1 2028." Sets correct expectations: multi-round company, not fast-to-revenue.

❌ Bad: "We will pursue Breakthrough Device designation to accelerate our pathway." Breakthrough is a designation, not a pathway. It does not replace a 510(k), De Novo, or PMA submission. Writing it at the top of the slide tells any reg-affairs-literate reader on the investment committee that the team does not know the difference.

How clinical trial milestones VCs gate map to the round you are raising

The FDA milestones slide is the gating document for Series A readiness. More than 70% of exiting companies in 2024 raised no further than Series A (PitchBook-NVCA), which means the Series A partner's underwriting is the last chance many of these companies get. Capital invested at Series B rose 17.3% in 2024 (Carta), but getting there requires that partner to model a pathway they understand. A legible FDA milestones deck slide is what lets them do that without a biotech co-investor holding their hand.

If you are sending more than 20 of these decks, tools like Causo handle the research and per-partner tailoring automatically. For lower volume, a named-partner spreadsheet is enough.

FAQ

How do you explain FDA to a non-bio VC? Start with one sentence of the form "Class [I/II/III] device pursuing [510(k) / De Novo / PMA], modeled on [named company]." Do not open with regulatory history or agency structure. Generalist VCs benchmark your risk against companies they already know, so anchor to a comp inside the first line.

What FDA milestones do VCs care about? Four, in this order: pre-submission meeting scheduled, submission filed, clearance or approval granted, first commercial use. Partners use these as binary de-risking events. Everything else is noise to a generalist.

Should I put 510(k) in my deck? Yes, if it is accurate. Name the pathway explicitly. Vague language like "pursuing FDA clearance" reads as evasion. If you are filing a 510(k), say 510(k) and name the predicate device on the same slide.

What is the difference between PMA and 510(k) for startups? 510(k) requires substantial equivalence to a cleared predicate and typically clears in 3 to 12 months. PMA is for Class III devices, requires clinical data from pivotal trials, and takes 24+ months. The pathway you file determines your capital plan, not the other way around.

How do VCs value medical device companies before FDA clearance? Pre-clearance value is a function of pathway risk, comp-based revenue ceiling, and how many gating milestones remain. Investors discount Class III / PMA companies more steeply because each milestone is further out. Comping to a cleared public or acquired company with the same pathway is the most common valuation anchor.